Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation

被引：0
|
作者：
Patel, H. [1 ]
Khalid, J. M. [1 ]
Shah, S. [2 ]
Shah, R. [3 ]
Berger, A. [2 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, Evidence & Value Generat, London, England
[2] Evidera, Real World Evidence, Waltham, MA USA
[3] Evidera, Real World Evidence, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P552
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [1] EARLY USE OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD ANALYSIS OF HEALTHCARE UTILIZATION
    Patel, Haridarshan
    Khalid, Javaria M.
    Shah, Surbhi
    Shah, Rikisha
    Berger, Ariel
    GASTROENTEROLOGY, 2018, 154 (06) : S371 - S371
  • [2] Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naive Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational Study
    Ferreira, S.
    Chebli, J. M. F.
    Parra, R.
    Sassaki, L. Yukie
    de Mello, M. K.
    Luporini, R. L.
    Chebli, L. A.
    Nobrega, F. J. Firmino
    da Silva, B. C.
    Dutra, R. D. M.
    Vasconcelos, J. R. de Oliveira
    Sales, M. P. Moraes
    Feres, O.
    Parente, J. M. L.
    Troncon, L. E. D. A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1087 - I1088
  • [3] Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease
    Latremouille-Viau, D.
    Burne, R.
    Shi, S.
    Adsul, S.
    Patel, H.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S295 - S296
  • [4] A real-world study of outcomes in biologic-naive patients with Crohn's disease and ulcerative colitis initiating vedolizumab
    Raluy, M.
    Alam, N.
    Donaldson, R.
    Smyth, M.
    Khalid, J. M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S238 - S238
  • [5] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF VEDOLIZUMAB VS. ANTI-TUMOR NECROSIS FACTOR IN BIOLOGIC-NAIVE ULCERATIVE COLITIS PATIENTS IN A NATIONWIDE HEALTHCARE PROVIDER DATABASE IN ISRAEL
    Weil, C.
    Chodick, G.
    Tsukinovsky, S.
    Ben Baruch, O.
    Barak, M.
    Sommer, A.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [6] Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
    Narula, Neeraj
    Wong, Emily C. L.
    Marshall, John K.
    Colombel, Jean-Frederic
    Dulai, Parambir S.
    Reinisch, Walter
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (07) : 1588 - +
  • [7] Vedolizumab is superior to infliximab in biologic naive patients with ulcerative colitis
    Sablich, Renato
    Urbano, Maria Teresa
    Scarpa, Marco
    Scognamiglio, Federico
    Paviotti, Alberto
    Savarino, Edoardo
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Yamamoto, Takayuki
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (05) : 546 - 547
  • [9] Cytomegalovirus Colitis Is Rarely Observed After Initiation of Infliximab, Adalimumab, or Vedolizumab in Biologic-Naive Patients With Ulcerative Colitis
    Dalal, Rahul S.
    McClure, Emma L.
    Pruce, Jordan C.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S334 - S335
  • [10] Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis
    Dignass, Axel U.
    Siegmund, Britta
    Goertz, Ralf
    Schneidewind, Gundula
    Fanter, Lena
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2019, 54 (02) : 178 - 187
12345